Significantly reduced abilities to cross-neutralize SARS-CoV-2 variants by sera from convalescent COVID-19 patients infected by Delta or early strains

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine induced sera

(2021) Daming Zhou et al.   CELL

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

(2021) Constantinos Kurt Wibmer et al.   NATURE MEDICINE

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

(2021) Chang Liu et al.   CELL

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

(2021) Delphine Planas et al.   NATURE

Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile

(2021) Alejandro Jara et al.   NEW ENGLAND JOURNAL OF MEDICINE

SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination

(2021) Markus Hoffmann et al.   Cell Reports

Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding

(2020) Tyler N. Starr et al.   CELL

Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting

(2020) Fran Robson et al.   MOLECULAR CELL